Fresh analysis reveals that patients who come off blockbuster slimming jabs like semaglutide or tirzepatide tend to recover lost weight far faster than those who stop conventional diet and exercise regimens.
Findings released in a prominent medical journal shows that while obese individuals often shed about a fifth of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users buying such medications should be cognizant of the risk of fast weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
This pace of regain means a return to pre-treatment mass in about a year and a half.
Weighing Treatments
The research, which reviewed dozens of trials involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with older methods.
The team note that people who lose weight through dieting typically experience a more gradual creep back—perhaps 0.1 kg a month—after stopping.
The Reason for the Fast Rebound
Doctors believe the mechanism of the drugs is key to understanding the accelerated weight return.
The injections copy a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal could lead to the system to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making binge eating much more probable."
A Lifelong Disease?
Health authorities recommend the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Professionals argue that, due to the high risk of weight regain, the therapy might need to be long-term.
This view is echoed by drug manufacturers, who note that the findings "underscore the persistent nature of excess weight," similar to managing diseases like diabetes.
Patient Accounts
People who have discontinued the jabs report a powerful return of appetite.
"I experienced something flipping and I was suddenly starving," described one woman.
The struggle is worsened if users have not established sustainable dietary or behavioural modifications during treatment.
Growing Adoption
Figures show that a significant number of people in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Use is greater among females compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, experts caution that while these medications are potent agents for shedding pounds, they are not a magic solution and maintained weight loss likely depends on combined lifestyle changes.
